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Abstract
It is of considerable translational importance whether
depression is a form or a consequence of sickness
behavior. Sickness behavior is a behavioral complex
induced by infections and immune trauma and
mediated by pro-inflammatory cytokines. It is an
adaptive response that enhances recovery by
conserving energy to combat acute inflammation.
There are considerable phenomenological similarities
between sickness behavior and depression, for
example, behavioral inhibition, anorexia and weight
loss, and melancholic (anhedonia), physio-somatic
(fatigue, hyperalgesia, malaise), anxiety and
neurocognitive symptoms. In clinical depression,
however, a transition occurs to sensitization of
immuno-inflammatory pathways, progressive damage
by oxidative and nitrosative stress to lipids, proteins,
and DNA, and autoimmune responses directed
against self-epitopes. The latter mechanisms are the
substrate of a neuroprogressive process, whereby
multiple depressive episodes cause neural tissue
damage and consequent functional and cognitive
sequelae. Thus, shared immuno-inflammatory
pathways underpin the physiology of sickness
behavior and the pathophysiology of clinical
depression explaining their partially overlapping
phenomenology. Inflammation may provoke a Janus-
faced response with a good, acute side, generating
protective inflammation through sickness behavior
and a bad, chronic side, for example, clinical
depression, a lifelong disorder with positive feedback
loops between (neuro)inflammation and (neuro)
degenerative processes following less well defined
triggers.
Keywords: depression, sickness behavior, inflamma-
tion, oxidative stress, cytokines
Introduction
The first inkling that there are phenomenological similari-
ties between clinical depression and sickness behavior and
that both conditions may share common pathways, that is,
activation of the inflammatory responses system (IRS) was
published in 1993 [1,2]. Sickness behavior is a behavioral
complex that is typically induced by acute infections and
tissue injury in many mammalian species. The characteris-
tic behavioral pattern consists of malaise, hyperalgesia,
pyrexia, listlessness and disinterest in social interactions
with the environment, lethargy, behavioral inhibition,
reduction of locomotor activity, exploration and grooming,
reduction of reproductive performance, anhedonia, som-
nolence and sleepiness, anorexia and weight loss, failure to
concentrate, and anxiety. There is evidence that sickness
behavior is mediated through the effects of pro-inflamma-
tory cytokines (PICs), such as IL-1, TNFa and IL-6 [3-10].
In this context, there is abundant evidence that clinical
depression is an immuno-inflammatory disorder charac-
terized by among other things increased levels of PICs and
acute phase proteins, including C-reactive protein and
haptoglobin [11-20].
Characteristic symptoms of major depression include
anorexia, weight loss, fatigue, lethargy, sleep disorders,
hyperalgesia, reduction of locomotor activity, and failure
to concentrate (American Psychiatric Association).
Moreover, ‘vegetative symptoms’ of depression, such as
anorexia, weight loss, and psychomotor retardation, are
significantly associated with inflammatory markers in
clinical depression, such as increased levels of plasma
haptoglobin, an acute phase protein, synthesis of which is
induced by the three abovementioned PICs [1,2].
Thus, it may be concluded that there are striking
behavioral and inflammatory similarities between both
sickness behavior and clinical depression [1,2,11].
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Therefore, some authors regard clinical depression as a
form of sickness behavior and/or as a consequence of
the sickness behavioral response [9]. Figure 1 shows the
theory - principally derived from inflammatory transla-
tional models - that inflammatory triggers cause IRS
activation and induce the production of PICs, which in
turn may provoke sickness behavior and depression,
thus explaining the phenomenological overlap between
these conditions.
The main aims of this paper are to delineate: a) the
symptomatic and behavioral similarities and dissimilari-
ties between both clinical depression and sickness beha-
vior; b) the staging of depression versus the course of
sickness behavior; c) the shared immuno-inflammatory
pathways that both underpin clinical depression and
sickness behavior and may discriminate them; and d)
the etiologic factors in both conditions.
The nature of sickness behavior
Inflammatory inducers, for example acute viral and bac-
terial infections and inflammatory trauma, are detected
by sentinels (for example, receptors on the innate
immune system) and activate inflammatory mediators,
for example, PICs which target the immune cells in the
inflamed tissues [21]. Adaptive inflammatory responses
are terminated once the triggers are eliminated and
damaged tissues are repaired, a phenomenon known as
resolution of inflammation. As we will explain in this
section PIC-induced sickness behavior plays an impor-
tant role in the resolution of inflammation and
increased energy demands during inflammation.
Sickness and energy consumption
Combating pathogen threats consumes large amounts of
energy and, therefore, rations available energy [22]. PIC
signals, for example, TNFa signals, modulate the bal-
ance between this increased energy demand and energy
supply and control food intake, energy expenditure and
substrate utilization [23,24]. PICs play a key role in this
highly increased energy request characterized by a nega-
tive energy balance (increased lipolysis, loss of tissue
proteins and lowered muscle protein synthesis, gluco-
neogenesis) and decreased voluntary energy utilization
[22]. The central nervous system (CNS) receives neural
and humoral signals about the peripheral inflammatory
response through PIC-induced activation of afferent
vagal signals, effects of TNFa at the sensory nuclei of
the solitary tract, and all three PICs entering the brain
though different pathways [22,25]. These PICs, in turn,
will shut off energy-consuming processes, such as loco-
motor, neurocognitive and reproductive activity. Thus,
metabolic energy is withdrawn from the brain and some
peripheral organs and redirected to counteract the
adverse effects of the invading pathogens. The energy
saved by this process contributes to pyrexia and to the
enhancement of the inflammatory state of immune cells
[22]. Many of the sickness behavior symptoms, such as
anergia, malaise, somnolence, psychomotor retardation,
cognitive deficits and loss of libido serve to limit motor,
sexual and brain activity and thereby direct metabolic
energy to combating the primary infection [4,7,22,26].
Immune responses are highly calorie dependent and
increase resting energy expenditure, while sickness beha-
vior responses, for example, motor inhibition, may con-
serve critical energy [27].
Sickness behavior and pyrexia
Mild to moderate pyrexia (in contrast to high fever) is a
positive adaptive response as it strengthens the host
defenses and resistance to infection, for example, by
enhancing the phagocytosis and mobility of polymorpho-
nuclear leukocytes and killing of bacteria and preventing
viral replication [28-30]. In addition, PICs and cytokines,
such as IFNs are more active during fever [31]. The rela-
tive balance of pyrogenic IL-1 and non-pyrogenic IL-18,
and their endogenous inhibitory factors in different CNS
sites, may contribute to the presence and degree of pyr-
exia [32]. In the past, fevers were even induced in
patients to combat infections.
Sickness behavior and anorexia and weight loss
Inflammation-induced anorexia is directly proportional to
the magnitude of the insult and is also inversely related to
body weight prior to the insult [33]. It is suggested that
anorexia may limit the intake of iron, which otherwise
would activate bacterial production [34]. Iron is one of the
nutrients employed by bacteria for bacterial growth. This
reasoning is, however, highly speculative as only less than
1% of dietary iron is absorbed and iron status changes
slowly over time. A more plausible adaptive function is
that anorexia through calorie restriction attenuates
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Figure 1 Inflammation causes sickness and depression. This
Figure shows the theory that acute triggers cause inflammation and
increased production of pro-inflammatory cytokines (PICs), which is
associated with the onset of sickness behavior and clinical
depression.
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different intracellular signaling pathways leading to inflam-
mation and even sickness behavior [35,36]. Thus, a two-
week calorie restriction period significantly reduces
inflammatory pathways, including IL-6 [37]. Calorie-
restriction results in a dose-dependent suppression of lipo-
polysaccharide (LPS)-induced sickness behavior by indu-
cing an anti-inflammatory state [36]. Motor inhibition and
anorexia can lead to lean body mass loss, increased protein
catabolism and loss of body protein and fat mass, which
together may explain inflammation-induced weight loss
and eventually cachexia. In the short-term, weight reduc-
tion, but not the composition of the diet, attenuates the
inflammatory response, for example, by lowering inflam-
matory PICs, such as IL-6 and TNF [38-40] and increasing
plasma levels of adiponectin, an adipose-derived anti-
inflammatory protein [41].
Figure 2 shows the different functions of acute inflam-
mation-induced sickness behavior. Thus, sickness behavior
is a short-term response to acute inflammatory triggers
and is an adaptive motivational state induced to cope with
these triggers and the consequent negative energy balance
[4,7]. This homeostatic adaptive behavioral response is
conserved across species through evolution and occurs in
a predictable form cross-culturally [26].
Symptomatic/behavioral similarities and dissimilarities
between depression and sickness behavior
The Diagnostic and Statistical Manual of Mental Disor-
ders (DSM IV-TR, American Psychiatric Association),
one of the most commonly used diagnostic systems for
psychiatric disorders, considers that the diagnosis of
clinical depression can be made when at least five out of
nine basic symptoms sare present for at least two weeks.
Table 1 lists these nine basic symptoms and also three
partially overlapping symptom dimensions that may
superimpose on these basic symptoms, that is: 1) melan-
cholic; 2) anxiety; and 3) physio-somatic dimensions
[15]. It should be stressed that multivariate statistical
analyses (pattern recognition methods) have confirmed
and validated the basic symptoms of clinical depression
and also the three symptom dimensions [42-44]. These
three dimensions delineate specific depressive sub-
groups, for example, depression with melancholic, anxi-
ety or physio-somatic features, which were externally
validated by biomarkers.
Table 1 compares the symptoms of clinical depression
with the characteristics of sickness behavior. Basic
symptoms/behaviors of clinical depression are also
observed in sickness behavior, for example, anorexia,
weight loss, reduction of locomotor activity and explora-
tion, fatigue, sleepiness, and failure to concentrate.
Moreover, symptoms belonging to the three dimensions,
for example, melancholia (a failure to react to pleasur-
able stimuli, and excessive psychomotor retardation and
weight loss) anxiety, and physio-somatic symptoms
(malaise and hyperalgesia) also occur during sickness
behavior. An apparent difference between depression
and sickness behavior is pyrexia. There are, however,
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Figure 2 This figure shows the functions of acute inflammation-induced sickness behavior: a) energy saving by protecting the organism
from the energy consuming effects of inflammation (through somnolence, lethargy, sleepiness, hyperalgesia, reduction of motor activity,
exploration and grooming, cognitive deficits, loss of libido, anhedonia, disinterest in social interactions with the environment, and anxiety); b)
anti-inflammatory effects (through anorexia, weight loss); and c) pathogen-directed effects (through pyrexia).
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some reports that major depressed patients have
increased body temperature as compared to normal
volunteers, that is 98.38 ± 0.61 degrees F versus 98.13 ±
0.59 degrees F, respectively (mean ± SD) (that is, 36.88°
C versus 36.74°C [45]. Increased body temperature in
clinical depression is also shown by Szuba et al. [46].
However, there is by no means conclusive evidence of
significant pyrexia in patients with clinical depression.
Obvious differences are suicidal ideation, feelings of
guilt and worthlessness, symptoms indicating a
distinctive existential state of depression [26]. In this
context, it is important to note that Charlton proposed
the malaise theory of depression, that is, malaise, the
key symptom of sickness behavior, should be considered
the core ‘emotion’ of depression. Indeed, a flu-like
malaise or the subjective feeling of infection together
with other physio-somatic symptoms is an important
symptom dimension in clinical depression [44]. The
malaise theory regards lowered mood and the more dis-
tinctive existential state of depression as a product of
Table 1 Characteristics of depression and sickness behavior.
Clinical depression Sickness behavior
Basic
symptoms
Depressed mood most of the day
Decreased interest or pleasure in almost all activities
Anorexia, and/or significant weight loss or weight gain
Insomnia or hypersomnia
Psychomotor agitation or psychomotor retardation
Fatigue or loss of energy
Decreased ability to think or concentrate
–
Disinterest in social interactions
Anorexia and weight loss; no weight gain
Sleepiness
Reduced locomotor activity; no agitation
Lethargy
Failure to concentrate
Existential
symptoms
Feelings of worthlessness or guilt
Suicidal ideation or behavior
–
–
Melancholic
dimension
A distinct quality of depressed mood (anhedonia)
Non-reactivity
Diurnal variation
Early morning awakening
Psychomotor retardation
Excessive weight loss
Reduced intake of sweetened milk (anhedonia)
Behavioral inhibition
–
–
Reduction of locomotor activity and exploration
Important weight loss
Anxiety
dimension
Tension; physiological behavior; respiratory symptoms; genito-
urinary symptoms; autonomic symptoms; anxious behavior at
interview (general)
Anxiety
Physio-
somatic
dimension
Flu-like malaise; aches and pain; muscle tension (in some of the
patients)
Malaise and hyperalgesia (key symptoms of sickness)
Pyrexia Slightly increased body temperature Pyrexia
Onset
Course
Insiduous
Waxing and waning or relapsing-remitting
Chronic
Sensitization of episodes
Seasonal variation
(Hypo)manic episodes
Acute onset
Acute adaptive response, maximal 19 to 43 days
May be prolonged, but then is maladaptive
–
–
–
Pathways (Sub)chronic inflammation with increased PICs
CMI activation
Sensitization of inflammatory and CMI pathways
Activation TRYCAT pathway
O&NS
Damage by O&NS
Autoimmunity
Neuroprogression
Acute inflammation with increased PICs
Activated
–
Maybe activated TRYCAT pathway
Unknown but probably yes
–
–
–
Triggers Multiple, not well defined
Psychosocial stressors, medical inflammatory illness,
neuroinflammatory disorders, inflammatory conditions
Acute, highly defined
Acute pathogens and tissue injury
Episodes tend to become autonomous from trigger Is always a response to a defined trigger
General Inflammation-related chronic progressive disorder Inflammation-induced adaptive behavioral response that is
conserved through evolution
PICs’ Janus-
face
Bad ‘chronic’ side: a chronic disorder with positive feedback loops
between (neuro)inflammation and (neuro)degenerative processes
Good ‘acute’ side: supports inflammation, redirects energy to
immune cells, conserves energy and prevents negative energy
balance, helps eradicating the trigger, and has anti-inflammatory
effects
CMI, cell-mediated immune; O&NS, oxidative and nitrosative stress; PICs, pro-inflammatory cytokines; TRYCAT, tryptophan catabolites.
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malaise. Thus, humans who suffer from sickness beha-
vior and do not know they are ill, may interpret their
lack of energy and neurocognitive disorders as a perso-
nal failure, causing feelings of guilt and unworthiness
[26]. By inference, this theory considers depression not
primary as an affective disorder but as a somatic disor-
der related to sickness behavior. Nevertheless, multivari-
ate statistical analyses show that only some depressed
patients suffer from physio-somatic symptoms, including
malaise [44]. These findings contrast with the view that
malaise is a core emotion of depression.
Staging of depression versus the course of sickness
behavior
Although some patients may suffer from one depressive
episode only, longitudinal studies performed within the
last two decades have shown that clinical depression is
typically an episodic or lifelong disease [47-49]. Although
depression was classically considered to be a self-limiting
disorder with a short duration (six to nine months), the
course of depression varies considerably. It may take the
form of prolonged episodes (chronic depression), and
depressive episodes may frequently return (recurrent
depression). Moreover, up to 15% of depressed patients
may develop treatment resistance, defined as a failure to
respond to at least two adequate antidepressant trials
[50]. A subgroup of depressed patients additionally suffer
from hypomanic or manic episodes (bipolar depression),
including abnormally elevated mood, energy and cogni-
tion; or from a mixed state with depressive and (hypo)
manic symptoms occurring together. It should be under-
scored that the brain is one of the most metabolically
active tissues, and energy and mood are intertwined.
Depression is linked to reductions in brain energy gen-
eration and mania to increased energy expenditure [51],
while sickness behavior is a behavioral response, which
conserves energy.
Both unipolar and bipolar depression have characteris-
tics of a progressive illness: they both follow stages, often
commencing with mild or non-specific symptoms, pro-
gressing to prodromal features of subthreshold symptoms,
then an acute episode, recurrence or a chronic form of
persistent, unremitting illness [16,17,48]. An earlier onset
of depression and increased length and number of epi-
sodes are associated with increased vulnerability to further
relapses and a less favorable outcome [16,17,52]. This pro-
gressive course is associated with a functional deteriora-
tion, including neurocognitive decline [53,54]. This
‘waxing and waning’ pattern is similarly characteristic of
autoimmune, progressive or degenerative disorders that
combine an insidious onset with recurrent episodes or a
chronic course and increased risk for functional deficits
[11]. Moreover, there is evidence that sensitization offers a
model for episode recurrence [55]. Sensitization indicates
that repeated exposure to stressors, either psychological or
organic, causes time-dependent, progressive increases in
susceptibility to re-exposure to any of these stressors
[56,57]. McEwen’s allostatic load model has similarly been
adapted to describe this progressive pattern [58]. More-
over, a seasonal variation is often found in unipolar and
bipolar depression and depressive subgroups, including
postpartum depression, with, for example, peak occur-
rences in spring [59,60]. There is also a seasonal variation
in severity of depression and depressive symptoms, includ-
ing suicide [61].
In contrast, sickness behavior is an acute, short-term
state most often with an acute onset that is biologically
appropriate to combat acute infections/trauma and thus
enhances recovery. Evidently, (hypo)manic symptoms, the
progressive deterioration over time, and seasonal variation
are not characteristics of sickness behavior. Sickness beha-
vior may be prolonged or inappropriately activated. Such a
prolonged sickness behavior complex is likely to be dys-
functional [26] as is the case in more chronic infections
and (auto)immune disorders. Motor and activity deficits
are typically associated with sickness behavior [62,63] and
form part of the fatigue - depression - sleep disorder clus-
ter occurring during acute and chronic illnesses including
heart disease, rheumatoid arthritis, and cancer [64]. In
some individuals these symptoms can persist years after
hospitalization, for example, post ICU and post-adminis-
tration of radioactive substances. The question arises as to
whether this condition should be regarded as sickness
behavior given it is no longer beneficial? The following
sections will address this question.
Pathways underpinning clinical depression and sickness
behavior
Inflammation and cell-mediated immunity
Studies in humans and rodents have defined PICs as cen-
tral mediators of sickness behavior [5,6,65-67]. Inflamma-
tory triggers induce ‘neuraxes’, that is, ascending neural
pathways, which convey information about metabolic, gas-
tro-intestinal and cardiovascular challenges to brain
regions that mediate stress-related behaviors [68,69]. For
example, infection and immune activation activate bot-
tom-up, inflammatory pathways, mediated by PICs, from
the periphery to the dorsal vagal complex, and ventrolat-
eral medulla of the caudal medulla [9,70-72]. These
inflammatory challenges to internal bodily functions are
translated into the brain via viscerosensory pathways that
subsequently drive sickness behavior, and depressive- and
anxiety-like behaviors [72]. Moreover, PICs are actively
transported to the brain by endothelial cell transporters or
may diffuse through blood-brain-barrier deficient areas
[25,72]. This may explain why systemic inflammation pro-
vokes neuroinflammation and microglial activation. For
example, administration of LPS, a component of the
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bacterial wall of gram negative bacteria, causes neuroin-
flammation and microglial activation, characterized by
increased levels of TNFa, which may remain elevated for
months and are associated with the onset of sickness
behavior [8]. Moreover, the same pathways may activate
brain regions, for example, the bed nucleus of the stria ter-
minalis, that mediate threat-related information and infec-
tion-induced anxiety [71,73-75]. Studies investigating the
mechanisms of these behavioral deficits in acute illness
models have shown that peripheral inflammation leads to
activation of a ‘danger pathway’ that originates in the cau-
dal brainstem and signals the presence of physiological
stressors to regulatory brain regions including the
hypothalamus. Activation of this danger pathway leads to
the suppression of hypothalamic arousal systems, notably
the tuberomammillary histaminergic system, associated
with behavioral activity [68]. When activation of the dan-
ger pathway is prevented, motor aspects of sickness beha-
vior are absent following acute inflammatory challenge
[69]. Thus, reduction in behavior associated with sickness
is concomitant with an active inhibition of arousal systems
[76]. The danger pathway also provides input to other
brainstem areas involved in the regulation of arousal
including the serotonergic dorsal raphe nucleus [68,69],
and in this way may serve as a link between peripheral
inflammation and brain functions regulating and/or influ-
enced by alterations in arousal states.
As reviewed previously, clinical depression and sickness
behavior share the involvement of key pathways, the pre-
dominant one being the role of inflammation [15]. In
clinical depression there is evidence of a chronic, low
grade inflammatory process and cell-mediated immune
(CMI) activation characterized by a T helper (Th1)-like
response with activation of IFNg-related pathways
[77,78]. Recent meta-analyses and recent publications
have confirmed increased levels of PICs in human
depression particularly IL-6, TNFa, and IL-1, and CMI
activation, evidenced by higher levels of neopterin and
soluble IL-2 receptors (sIL-2Rs) [18-20,79,80]. Increased
neopterin is a marker of increased IFNg mediated macro-
phage activation. In humans, IFNa-based immunother-
apy induces physio-somatic and depressive symptoms in
many patients with hepatitis C virus. The onset of
depressive symptoms during IFNa-based immunotherapy
is strongly associated with induction of the cytokine net-
work, including elevations in monocytic cytokines, Th-1-
like and Th-2-like cytokines [18,81,82].
Elevated PICs and CMI cytokines are capable of produ-
cing depressive symptoms and administration of cytokines
provides a robust experimental model of the acute phase
of depression. Studies in the rodent [15] provide strong
evidence that PICs, for example IL-1, IL-6, and TNFa, and
CMI cytokines, for example IL-2 and IFNg, all at around
50 μg/kg, may induce: a) sickness behavior; b) depressive-
like symptoms (including loss of motivated behavior,
reduction of social investigation, anorexia, weight loss,
decreased spontaneous locomotor activity, increased loco-
motion, memory impairment, impaired spatial memory,
and enhancement of the amnesic effect of scopolamine);
c) melancholic symptoms (including anhedonia as indi-
cated by reduced preference for a solution of sucrose or
chocolate milk in comparison to water, and changes in the
circadian clock through effects at the suprachiasmatic
nucleus); d) anxiety (including anxiogenic effects in the
elevated plus maze and elevation of conditioned fear
memory); and e) physio-somatic symptoms (including fati-
gue, hyperalgesia, and autonomic symptoms). Administra-
tion of LPS elicits not only sickness behavior but also
depressive- (suppression of social interaction and activity
in the open-field test, food consumption and body weight,
memory dysfunction), anxiety-like and physio-somatic
behaviors [15]. Cytokines such as IL-1 not only have
potent primary signaling effects, but also modulate many
neurotransmitters intimately involved in mood regulation
such as serotonin and noradrenaline [83]. Recently, the
inflammatory processes were linked with the neurocircui-
try hypothesis of depression [84]. Thus, PICs modulate
cortical-striatal-limbic circuits, which process reward-
based and affective information and are responsible for
core depressive symptoms [84].
Certainly, it is difficult to determine whether the depres-
sogenic and anxiogenic effects of LPS and other inflamma-
tory triggers are genuine or related to sickness behavior
[85]. Since cytokine- and LPS-based models are accompa-
nied by depressive-like and sickness behaviors it was often
difficult to delineate which of these models are character-
istic for acute depressive-like behaviors or for sickness
behavior. Nevertheless, some groups have apparently sepa-
rated initial sickness behavior from depressive-like beha-
viors. Dissociation between LPS-induced depressive-like
behaviors and sickness behavior could be established by
testing mice at different time points following administra-
tion of LPS [86]. Lacosta et al. (1999) [87] showed that sys-
temic administration of IL-2 to mice induces reductions in
exploration and impaired performance in the Morris
water-maze that are not related to sickness behavior.
Administration of intracerebroventricular (icv) IL-1b
induces a sickness behavioral response (as indicated by
reduced locomotor activity, lethargy, and reduced body
weight) and a stress- or anxiety-like response [88].
Activation of the IRS is controlled at different levels
whereby regulatory mechanisms specifically target selected
control points, such as the production of pro-inflamma-
tory mediators or the effects of mediators on the target tis-
sues [21,89]. This regulation of the IRS response is an
adapted compartmentalized regulatory response character-
ized by reflex inhibition that tends to silence an overzea-
lous IRS [90]. Examples of inflammatory reflex inhibition
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are inflammation-induced increases in IL-10, a negative
immunoregulatory cytokine, and transforming growth fac-
tor (TGF)b, an antiproliferative factor [21]. PIC-induced
changes in neural pathways also participate in inhibiting
acute inflammation, for example, enhanced production of
glucocorticoids and catecholamines, and activation of cho-
linergic pathways [91]. For example, counter regulatory
mechanisms are initiated to limit an infectious (sepsis) and
non-infectious systemic inflammatory response syndrome
[90,92,93]. This counter anti-inflammatory response syn-
drome is an adaptive response of the immune status that
dampens an overzealous inflammatory response caused by
pathogens or immune trauma [90,92,93].
The existence of comparable counter regulatory pro-
cesses, in particular reflex inhibition, has been described in
clinical depression [11,78]: increased synthesis of the IL-1
receptor antagonist (IL-1RA), which inhibits the function
of IL-1; PIC-induced activation of the cortisol-axis and the
consequent immunosuppressive activities of glucocorti-
coids; increased IL-6 production, which is protective by
increasing the production of IL-10, IL-1RA and glucocorti-
coids; increased IL-2R levels which induce a state of IL-2
starvation by binding their ligand and limiting the amount
of IL-2 needed for immune cell proliferation; increased
production of some acute phase proteins, for example, hap-
toglobin, which act as immunosuppressive factors;
increased prostaglandin production, which may suppress
lymphoproliferative responses; and lowered plasma trypto-
phan levels (see next section). These counter anti-inflam-
matory response syndrome mechanisms may explain why
the immune-inflammatory response in clinical depression
is accompanied by signs of immunosuppression, such as
decreased ex vivo natural killer cell activity and mitogen-
induced lymphoproliferative disorders [11]. In analogy with
the term counter anti-inflammatory response syndrome,
which is typically coined as a counter-regulatory response
to sepsis/systemic inflammatory response syndrome, we
would propose to label this compensatory reflex system as
‘compensatory (anti)inflammatory reflex system’ (CIRS).
Sickness behavior supports the protective inflamma-
tory response (helps to eradicate the trigger and redir-
ects energy to inflammatory cells), protects against
possible detrimental effects of inflammation (for exam-
ple, negative energy balance), while at the same time
acting as an anti-inflammatory reflex (anti-inflammatory
effects of calorie restriction and weight loss). Therefore,
sickness behavior itself should be regarded as a CIRS
response to acute inflammation. Thus, while clinical
depression is accompanied by a CIRS that downregu-
lates the immuno-inflammatory response, sickness beha-
vior is part of a CIRS.
The TRYCAT (tryptophan catabolite) pathway
Recently, a new pathway associated with inflammation
has been established in some individuals with
depression, that is, activation of the tryptophan catabo-
lite (TRYCAT) pathway [94-97]. The first and rate-limit-
ing enzyme of this pathway is indoleamine 2,3-
dioxygenase (IDO; EC 1.13.11.52) [98]. IDO is activated
by IFNg and by PICs, such as IL-1 and TNFa, thereby
inducing the catabolism of tryptophan leading to trypto-
phan depletion and increased synthesis of TRYCATs,
for example, kynurenine, kynurenic acid, xanthurenic
acid, and quinolinic acid. IDO is expressed in many
organs, for example, kidney, lung, spleen, and duode-
num, immune cells, and the brain, for example, astroglia
and microglia [99,100]. Lowered plasma tryptophan fre-
quently occurs in clinical depression and is strongly
associated with biomarkers of inflammation (acute
phase reactants, increased cytokine levels) and CMI acti-
vation (increased serum neopterin and sIL-2Rs) [94-96].
During IFNa-based immunotherapy the onset of depres-
sive symptoms is strongly associated with IDO activa-
tion, as assessed by means of the kynurenine/tryptophan
ratio [101]. Likewise, in the postnatal period lowered
tryptophan and increased IDO activity are related to
anxiety and depressive symptoms [102]. Acute trypto-
phan depletion causes a robust increase in depressive
symptoms in vulnerable individuals [103].
Recent studies have shown that IDO activation may
separate sickness behavior and depressive-like behaviors
in the rodent [104]. Thus, in Wild type (WT) mice,
inoculation with bacille Calmette-Guérin (BCG), an atte-
nuated form of Mycobacterium bovis, elicits IDO activa-
tion and consequent elevations in PICs and CMI-
cytokines, such as IFNg, IL-1b and TNFa [104]. Inocula-
tion with BCG caused an initial acute episode of sickness
behavior that was followed by a chronic state of depres-
sive-like symptoms starting one week after BCG adminis-
tration. Sickness behavior was equally induced in WT
and IFNgR(-/-) mice, whereas IFNg and TNFa together
are necessary to cause IDO activation in microglia and
consequent depressive-like behaviors. Moreover, IDO-
deficient mice are resistant to the depressogenic effects
of BCG, while they show a normal inflammatory
response following BCG administration [104].
These TRYCAT data obtained in animal experiments
are, however, difficult to extrapolate to clinical depres-
sion, because the clinical results are controversial. Thus,
initial research showed no changes in urinary excretion
of TRYCATs, such as xanthurenic acid and kynurenine,
after tryptophan loading in depressed patients [105-108].
Nevertheless, higher xanthurenic excretion rates were
related to anxiety and a lowered availability of plasma
tryptophan [105,108]. The latter findings show that a
‘TRYCAT shunt’ through activation of IDO lowered
plasma tryptophan in individuals with depression. In a
recent study [109], lower levels of kynurenic acid and
consequently a relatively increased kynurenine/kynurenic
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acid ratio were observed in depression. This ratio might
be important for the pathophysiology of depression as
kynurenine and some of its catabolites, for example, qui-
nolinic acid, are depressogenic, anxiogenic, excitotoxic
and neurotoxic, whereas kynurenic acid is neuroprotec-
tive [96]. One study shows increased TRYCATs in
adolescents with melancholic depression [110] and
another study increased quinolinic acid in microglia of
depressed suicide victims [111]. Sublette et al. [112]
detected increased plasma kynurenine levels in suicide
attempters with major depression. Recent data shows
that aberrations in the TRYCAT pathway, classically seen
as a hallmark of depression, may be more germane to
somatization, suggesting that the classically labeled psy-
chosomatic symptoms of somatization may be more
appropriately termed physio-somatic symptoms [113].
Thus, in a study comparing depression, comorbid depres-
sion + somatization, somatization alone, and controls,
plasma tryptophan was even lower in somatization than
in depression, while the kynurenine/kynurenic acid ratio
and the kynurenine/tryptophan ratio were significantly
higher in patients with somatization than depression
[113]. Plasma tryptophan was negatively, and both ratios
were positively, correlated with severity of physio-somatic
symptoms. In summary, although in acute inflammatory
states (for example, during IFNa-based immunotherapy)
IDO activation is strongly related to the onset of depres-
sive-like behaviors, this appears not to be the case in clin-
ical depression since only some of those individuals, that
is, those with physio-somatic symptoms or suicidal beha-
vior, show relative increases in TRYCAT levels.
IDO activation has protective CIRS functions: IDO-
induced reductions in plasma tryptophan and increased
TRYCAT formation may attenuate the primary immuno-
inflammatory response, for example, by attenuating T cell
activation and proliferation [11,15]. This reflex inhibition
could, therefore, be involved in spontaneous remissions of
clinical depression, consistent with the observation that
depression is sometimes a self-limiting disorder [96]. This
CIRS mechanisms may also explain the contradictory find-
ings on the TRYCAT pathway in acute depressive states
(for example, IFNa-induced depression where there is a
strong association between TRYCAT aberrations and the
onset of depression) and major depression (DSM-IV-TR
criteria), where these associations are much weaker prob-
ably because lowered tryptophan and increased TRYCATs
have attenuated the initial immune-inflammatory
response. Nevertheless, increased levels of TRYCATs, for
example, quinolinic acid, in the anterior cingulate gyrus
may be detrimental and play a role in clinical depression.
Detrimental immuno-inflammatory pathways that
discriminate depression from sickness behavior
Although there is some evidence that shared immuno-
inflammatory pathways may underpin sickness behavior
and clinical depression, they have divergent effects in
both conditions. Thus, the inflammatory response in
sickness behavior has a beneficial CIRS effect on the
organism, whereas inflammatory pathways and their
sequelae have detrimental effects in depression and in
particular in recurrent and chronic depression.
Transition to sensitization and autoimmunity
There is evidence that immuno-inflammatory responses
are sensitized by recurrent depressive episodes. Thus,
neopterin, a biomarker of CMI activation, is significantly
increased in depressed patients who have experienced
two or more depressive episodes than in patients who
suffered only one depressive episode [18,114]. Likewise,
plasma IL-1 and TNFa are significantly increased in
depressed patients who suffered from three or more
depressive episodes [18]. Women with a lifetime history
of depression have increased inflammatory biomarkers,
including IL-6 and sIL-1RA, in the early puerperium as
compared to women who have never suffered from
depression [115]. Increased C-reactive protein (CRP)
levels in depressed men predict not only severity of the
current depressive episode, but also recurrent depression
[116]. It is known that PICs mediate central sensitiza-
tion, for example, behavioral responses to maternal
separation [117,118]. This suggests that recurrent
depressive episodes amplify the pathophysiological
responses of depressogenic cytokines, potentially enhan-
cing inflammation-induced behavioral responses. Since
it is known that increased numbers of episodes increase
the risk of recurrence and treatment resistance [17], the
findings suggest that sensitization of immuno-inflamma-
tory pathways increases vulnerability to develop new
depressive episodes.
Immuno-inflammatory mechanisms may also explain
the high degree of anti-5-hydroxytryptamine (5-HT) anti-
body activity in clinical depression (54.1%), and in mel-
ancholia (82.9%) as compared to normal controls (5.7%)
[119]. This autoimmune activity directed against 5-HT is
significantly associated with biomarkers of inflammation
(increased IL-1 and TNFa) and CMI activation
(increased neopterin). In this respect, administration of
pro-inflammatory and CMI-related stimuli, including
LPS, IFNg, and TNFa, reduces the survival of 5-HT neu-
rons in the dorsal raphe nucleus, an effect that is not
related to IDO activation [120]. The autoimmune activity
directed against 5-HT is additionally associated with the
number of previous depressive episodes, suggesting that
exposure to previous depressive episodes increases anti-
5-HT antibody activity, which, in turn, could confer
increased risk to develop new depressive episodes.
Moreover, increased IL-6 and TNFa and lower serum
zinc levels are associated with risk for depression and
treatment-resistant depression [121-125]. This suggests
that the immuno-inflammatory response in clinical
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depression may confer increased risk towards treatment
resistance [126]. There is also evidence that immuno-
inflammatory processes underpin the pathophysiology
not only of unipolar and bipolar depression, but also
mania [127,128]. Acute mania is accompanied by
increased sIL-6R and sIL-2R levels, and increases in
acute phase reactants [127,128], increased sCD4, sCD8,
and sIL-1R antagonist levels [129], and elevated total
immunoglobulin (Ig) G1, complement proteins C3, C6
and factor B [130]. Recently, it was argued that immuno-
inflammatory processes play a role in the progressive
shortening of the inter-episode interval with each recur-
rence when bipolar depression progresses [16,17]. All in
all, the aforementioned findings suggest that sensitization
(kindling) and progression of depression and bipolar dis-
order are, in part, caused by progressive inflammatory,
CMI and autoimmune responses.
Transition to damage by O&NS processes
As with many inflammatory conditions, clinical depres-
sion is accompanied by activation of oxidative and nitro-
sative stress (O&NS) pathways [131]. The latter are likely
amplified by reduced antioxidant levels, for example,
coenzyme Q10, zinc and glutathione, and by the
immuno-inflammatory responses in depression, perpetu-
ating a vicious cycle between reduced antioxidants,
inflammation and activated O&NS pathways [131]. There
are no reports whether O&NS pathways play a role in
adaptive sickness behavior. Nevertheless, these pathways
have detrimental effects in clinical depression and addi-
tionally play a role in chronic depression. There is abun-
dant evidence that depression is characterized not only
by increased reactive oxygen and nitrogen species (ROS/
RNS), but also by O&NS damage to lipids, proteins,
DNA, and mitochondria [131]. In these processes O&NS
pathways may alter the chemical structure of membrane
fatty acids and functional proteins. When these modified
fatty acids and proteins become immunogenic, an auto-
immune response may be mounted directed against these
‘neoepitopes’ thereby further damaging the function or
chemical structure of these epitopes [132,133]. Many
depressed patients show increased IgM-mediated auto-
immune responses directed against neoepitopes, such as
the three anchorage molecules, palmitic and myristic acid
and L-farnesyl S-cysteine, as well as acetylcholine, phos-
phatidylinositol, oleic acid, and NO-adducts, including
NO-tryptophan and NO-tyrosine [133]. These autoim-
mune responses may interfere with cellular functions
including intracellular signaling, apoptosis, and cellular
differentiation. For example, the autoimmune reactions
directed against the anchorage molecules may interfere
with palmitoylation, myristoylation and farnesylation,
and, therefore, with the binding and function of hundreds
of proteins to the membrane [133]. Some of these IgM-
mediated autoimmune responses are significantly higher
in chronically depressed patients than in non-chronically
depressed patients, suggesting that this O&NS damage
may increase risk to develop chronic depression for
example by activating neuroprogressive pathways
[16,17,52,133]. These O&NS-related processes together
with the effects of inflammatory mediators at 5-HT neu-
rons [120] may explain the transition from inflammation
and CMI activation to damage by O&NS and autoim-
mune reactions, which both may aggravate the preexist-
ing inflammation and are involved in the process of
chronic depression.
Transition to neuroprogression
Another immuno-inflammation-related pathway, which
has detrimental effects in clinical depression and is not
germane in sickness behavior, is neuroprogression, that is
the stage related and potentially progressive process of
neurodegeneration, reduced neurogenesis and neuronal
plasticity, and apoptosis [15,17,123,126,134-137]. Many,
but not all depressed individuals show features suggestive
of a neuroprogressive illness. As discussed above, people
who have a longer duration of illness and suffered from
more frequent depressive episodes have a greater risk to
develop subsequent relapses. Treatment response appears
to reduce with more recurrent mood episodes [15,17,52].
Recurrent depressive episodes are correlated with
increased cognitive disabilities, for example, decreased
memory performance which is lowered by 2% to 3% fol-
lowing each depressive episode [138]. Depressive episodes
are additionally associated with an increased risk of
dementia [54]. Likewise, more depressive episodes are
associated with underlying brain alterations, for example,
reductions in volume of orbitofrontal and subgenual pre-
frontal cortex, hippocampus, and basal ganglia [52]. The
duration of illness, for example, is negatively correlated
with the volume of cerebral grey matter [139]. Meta-analy-
sis showed that in patients with chronic depression (> 2
years) or recurrent depression hippocampal volume is sig-
nificantly decreased and that the latter is related to the
number of episodes [140,141]. In some studies, decreased
hippocampal volumes in patients with recurrent depres-
sion are associated with neurocognitive decline [142].
Treatment resistance and the duration of illness are
related to decreased right caudate and left putamen
volume [52,143]. This effect may in part be related to a
decrease in soma size of some cell types [144]. There is
also evidence that in depression the abovementioned neu-
roprogression is at least partially caused by inflammatory
and O&NS pathways [15,17,126]. PICs, such as IL-1 and
TNFa, and CMI cytokines, for example, IFNg and IL-2,
TRYCATs, such as quinolinic acid, and damage by O&NS
to structural fatty acids, anchorage molecules, functional
proteins, DNA and mitochondria all may contribute to
neuroprogression [15,17,126]. Further, both immune chal-
lenge and depression influence a constellation of brain
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regions that process viscerosensory and regulation of emo-
tion in humans [145-147] and rodents [148]. These
regions include parts of the medial prefrontal cortex (ante-
rior cingulate) and basal forebrain (nucleus accumbens).
Intriguingly, the CIRS seems to weaken with progression
of the illness, and this failure to dampen inflammatory
activation might play a role in the process of neuropro-
gression seen with multiple episodes [149].
All in all, the abovementioned findings show that clinical
depression is accompanied by chronic inflammatory and
O&NS responses and/or its sequelae, including sensitiza-
tion, autoimmunity, damage by O&NS and neuroprogres-
sion. As a consequence, the inflammatory experiments
described in the previous sections do not provide mechan-
istic explanations as to how PICs and CMI cytokines
cause progressive clinical depression, as defined by its pro-
gressive course and progressive immuno-inflammatory
pathophysiology. These experiments nevertheless support
the view that PICs and CMI cytokines are associated with
the onset of depressive-like behaviors and the physio-
somatic, melancholic, and anxiety symptomatic clusters.
However, most of these LPS- and cytokine-induced mod-
els did not separate sickness behavior from depression. In
addition, these experiments are very limited because they
select only one or two aspects of the symptom dimensions
of depression, for example, reduced intake of sweetened
milk as a model for anhedonia and thus melancholia
[150]. More adequate animal models of clinical depression
should be constructed to model not only the symptomatic
dimensions, but also the typical course (self-limiting versus
waxing and waning or progressive course) and the
progressive pathophysiology (with sensitization and a tran-
sition to oxidative damage, autoimmunity and neuropro-
gression) of clinical depression.
Etiologic factors in depression and sickness behavior
Etiologically, sickness behavior is conceptualized as an
acute phase of adaptive CIRS behavior in response to
acute infections and inflammatory trauma [4,7,26]. When
the resolution phase, however, is not induced, for example,
when the IRS was unable to eradicate the pathogen,
inflammation may persist despite the CIRS thus causing a
chronic inflammatory state [21]. Chronic inflammation
may result from a failure to eradicate the acute inflamma-
tory trigger (for example, pyogenic bacteria), innately
chronic irritants (for example, fungi, sarcoidosis), or auto-
immune responses [151]. Acute and chronic inflammation
are distinguished in terms of immune response patterns
and time course. The time point of transition of acute
inflammation to chronic inflammation is also related to
the time when the energy stores become empty and this is
estimated to be around 19 to 43 days depending on the
nature of the energy store [152]. This transition is related
to a number of inflammatory sequelae, including cachexia,
insulin resistance, anemia, osteopenia and hypertension
[152]. Sickness behavior thus plays a critical role in pre-
venting the transition from acute to chronic inflammation
following an acute trigger by compensating for the nega-
tive energy balance, redirecting energy to the activated
immune cells, and so on [152]. Clinical depression, on the
other hand, is accompanied by chronic inflammatory pro-
cesses and is associated with less well defined trigger fac-
tors, as will be explained in this section.
In many chronic disorders, including degenerative (for
example, diabetes, atherosclerosis) and neurodegenerative
(for example, Parkinson’s disorder) disorders the initiating
trigger is not well defined, while the chronic state appears
to consist of positive feedback loops connecting chronic
inflammation and its pathophysiological process [21]. For
example, Parkinson’s disease (PD) is characterized by a
vicious cycle between microglial activation and dopami-
nergic neuron degeneration, caused by detrimental effects
of PICs, O&NS, and so on [25]. A similar pattern is
observed in clinical depression: a chronic inflammatory
process appears to be associated with transition to pro-
gressive autoimmune and neuroprogressive processes.
In contrast to sickness behavior, pathogens do not play a
major role in clinical depression although some authors
have attempted to make links between pathogens such as
herpes simplex type 2 and toxoplasma gondii and psycho-
pathology [153,154]. In a previous review, we concluded
that there is no good quality evidence that acute infections
and infections with Epstein-Barr Virus (EBV) may act as
trigger factors associated with the onset of clinical depres-
sion [155]. Only some types of chronic infection are fre-
quently associated with clinical depression, for example,
HIV infection [156] and increased translocation of gram
negative bacteria [157]. Some chronic infections, such as
Lyme’s disease can cause prominent neuropsychiatric
sequelae [158,159]. Thus, while sickness behavior is an
adaptive CIRS response to acute infections, only a few
chronic pathogenic conditions appear to be associated
with the onset of clinical depression. However, it cannot
be excluded that reactivated dormant infected states and
consequent infection-induced molecular pathways may be
important in clinical depression. Viral infections of the
brain, for example, cause neurologic and psychiatric dys-
function more often than appreciated [160].
Multiple trigger factors may provoke depressive beha-
viors, for example, psychosocial stressors, various medical
disorders, and conditions as different as hemodialysis,
IFNa-based immunotherapy, and the postnatal period
[25,65,80]. Psychosocial stressors in humans may induce
inflammatory, Th1-like and O&NS responses, including
lipid peroxidation and DNA damage, while in the rodent
different types of stressors induce peripheral and central
activation of inflammatory, O&NS and neuroprogressive
pathways [25,65,80,161]. For example, in the rodent, social
defeat stress increases the reactivity of microglia to LPS,
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suggesting a role for social stress factors in the regulation
of microglia responses [162]. Therefore, it may be con-
cluded that psycho-traumatic and psychosocial stressors
may cause depression and depressive-like behaviors
through activation of immuno-inflammatory, O&NS and
neuroprogressive pathways.
Many different medical disorders and conditions, which
are associated with immuno-inflammatory and O&NS
pathways, show a high comorbidity with depression: a)
medical disorders, such as chronic obstructive pulmonary
disease (COPD), cardiovascular disorder (CVD), chronic
fatigue syndrome, obesity and the metabolic syndrome,
rheumatoid arthritis (RA), systemic lupus erythematosus
(SLE), inflammatory bowel disease (IBD), psoriasis, osteo-
porosis, and diabetes type 1 and 2; b) neurodegenerative
or neuroinflammatory disorders, such as Alzheimer’s
(AD), PD and Huntington’s disease, multiple sclerosis
(MS) and stroke; and c) conditions, such as hemodialysis,
IFNa-based immunotherapy, and the postnatal period
[25,163]. We have argued that these disorders/conditions
are all accompanied by activation of immuno-inflamma-
tory and O&NS pathways and therefore may cause the
basic immune/inflammatory state which may lead to
comorbid depression [25]. Likewise, the same pathways
could induce sickness behavior, which is experienced as
feeling unwell, aches and pains, fatigue, and so on. How-
ever, while sickness behavior, per definition, is an adaptive
response, comorbid depression worsens the aforemen-
tioned medical conditions [25]. Concomitant depression
lowers the quality of life and increases disability and mor-
tality in individuals with COPD, CVD, RA, SLE, IBD, psor-
iasis and diabetes type 1 and 2. Comorbid depression also
contributes to lowered quality of life in individuals with
MS, PD, AD, and stroke, negatively influences recovery
from neurological defects, and predicts a higher morbidity
and mortality in individuals with those neurological disor-
ders. These negative effects of comorbid depression may
be explained by increases in (neuro)inflammatory burden,
including TRYCAT production, damage by O&NS, transi-
tion to autoimmunity and neuroprogression, which all
together may drive the (neuro)inflammatory progression
of the abovementioned medical conditions. During IFNa-
based immunotherapy the incidence of depression was
highest on the 12th week of treatment, when more than
20% of patients with Hepatitis C Virus had moderate/
severe depressive symptoms [164]. Physio-somatic symp-
toms, including fatigue, increased in the first week of treat-
ment, and predicted cognitive-depressive symptoms some
weeks to months later [165]. Thus, IFNa-based immu-
notherapy is probably one of the only trigger factors of
depression that is characterized by transition from an
acute inflammatory state (accompanied by sickness beha-
vior) to a chronic inflammatory state (accompanied by
depression).
Another factor that discriminates sickness behavior from
depression is that the former is a response to a specific
immune trigger, whereas the association between depres-
sogenic triggers and depression is not always present. For
example, as depressed people suffer from recurrent
depressive episodes, it is less likely that stressful triggers
are required to manifest depression. Following more than
nine previous episodes, the trigger - depression association
is muted and episodes appear autonomously, disconnected
from triggers [166]. Also this effect may be explained by
the knowledge that depression is a progressive disorder
and that depressive episodes become sensitized [17].
The above suggests that chronic animal models such
as the chronic mild stress and olfactory bulbectomized
rat model are superior to the acute cytokine or LPS-
induced models in that they: a) are less ‘contaminated’
with sickness behavior; and b) more accurately represent
the psychosocial etiology, and/or (neuro)inflammatory
and (neuro)progressive pathophysiology of clinical
depression. Thus, the chronic mild stress model in the
rodent shows that psychosocial triggers may cause
depression-like behaviors in association with systemic
and central inflammation and neuroprogression includ-
ing decreased neurogenesis and neuronal cell damage
[65]. The chronic mild stress model also mediates some
of its effects from the differential regulation of the TRY-
CATs in different parts of the CNS [167]. A differential
increase in quinolinic acid in the amygdala and striatum,
with a trend increase in kynurenic acid in the frontal
cortex following chronic mild stress would suggest an
important role for variable TRYCAT pathway activation
in mediating the changes associated with more psycho-
social type stressors. Such differential TRYCAT pathway
activation in different areas in the CNS may be relevant
in differentiating sickness behaviors from clinical
depression. Also, the olfactory bulbectomized rodent
model of depression reflects the (neuro)inflammatory
and neuroprogressive phenomena observed in clinical
depression [66,67,168,169].
Is prolonged, exaggerated or maladaptive sickness behavior
depression?
There is recent literature describing new concepts, such as
prolonged, exaggerated and maladaptive sickness behavior
[170,171]. In translational models, exaggerated inflamma-
tory and neuro-immune responses are associated with so-
called ‘prolonge’” sickness behavior, including memory
deficits. Such an exaggerated response is observed in aged
as compared to adult mice [170]. This age-dependent pro-
longed sickness behavior is accompanied by oxidative
damage to mitochondrial DNA (mtDNA) in microglia,
increased intracellular ROS and activation of nuclear fac-
tor kappa B [170]. Subchronic administration of IL-1b sig-
nificantly impairs spatial and learning memory, which is
correlated with dysfunction of neurotrophins and their
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receptors [172]. Furthermore, the release of neurotrans-
mitters, including acetylcholine, was significantly lower
during memory retrieval. In hippocampal neurons, IL-1b
administration significantly induced cell apoptosis,
reduced aa-amino-3-hydroxy-5-methyl-4-isoxazolepropio-
nic acid receptors, but increased N-methyl-D-aspartate
receptor changes similar to those observed in AD [173]. It
thus seems unlikely that depression is a maladaptive syn-
drome that results from prolonged ‘sickness behavior’ but
rather the consequence of a chronic underlying immuno-
inflammatory and degenerative process. These findings
also show that there was no resolution to acutely triggered
inflammation and consequently that transition towards
chronic inflammatory pathology had occurred. By infer-
ence, this condition cannot be termed ‘prolonged’ sickness
behavior, because the latter term indicates a short-term
adaptive response to inflammatory trauma. Nevertheless, a
valid conclusion is that shared pathways, for example,
increased levels of PIC, explain the partially overlapping
phenomenology of sickness behavior and clinical
depression.
There is also a new hypothesis that associates depression
as an evolutionary product of sickness behavior with pro-
tection from infection. As such depression is regarded as
an evolutionary behavioral response that helps the
immune system to fight pathogens and to avoid new
pathogen exposure [26,174,175]. These hypotheses, how-
ever, did not take into account that clinical depression is
not a simple behavioral response, but a progressive disor-
der driven by a cascading neurobiology leading to a pro-
gressive course and pathophysiology. Moreover, acute
lethargy, hyperalgesia, loss of interest, anxiety, and anhe-
donia are beneficial behaviors, but when chronic the same
symptoms are typically not beneficial, but pathological and
maladaptive: they may further isolate the depressed patient
from social contacts creating a state of demotivation and
demoralization and negative anticipation of the future
[26]. Chronic illness, furthermore, requires a person to use
coping and adaptive strategies to integrate the conse-
quences of a disorder. There is a wide diversity of coping
styles and beliefs on the nature of depression, some of
which are adaptive while others are maladaptive [176].
Antidepressive treatments
Antidepressants have significant immunoregulatory and
immunosuppressive effects in normal volunteers and ani-
mal models. Tricyclic antidepressants (TCAs) and selective
5-HT reuptake inhibitors (SSRIs) attenuate the production
of PICs, for example, IL-1b, TNFa and IL-6, and Th1-like
cytokines, including IL-2 and IFNg [177]. Most antidepres-
sants, that is, TCAs, SSRIs, reversible inhibitors of monoa-
mine oxidase A, 5-HT and noradrenaline reuptake
inhibitors, and atypical antidepressants (for example, tia-
neptine) all increase the production of IL-10, a negative
immunoregulatory cytokine and/or lower the production
of IFNg, resulting in a decreased IFNg/IL-10 production
ratio [178]. There is also evidence that SSRIs and TCAs
inhibit the production of IL-1b, TNF-a, and IL-6 in brain
cell cultures [65]. Also, in animal models antidepressants
have antiinflammatory effects [65]. Mice challenged with a
lethal dose of LPS are protected by bupropion administra-
tion, which significantly reduces the production of IFNg,
TNFa and IL-1b [179]. There is also evidence that antide-
pressants may attenuate inflammation-induced sickness
behaviors. For example, tianeptine may reduce sickness
behaviors induced by peripheral (but not central) adminis-
tration of LPS and IL-1b [180]. Treatments that target
inflammation, for example, etanercept that blocks TNFa
functions, may attenuate IL-1b-induced sickness behaviors
[181].
In depressed patients, on the other hand, the in vivo
effects of antidepressants are less clear. Subchronic treat-
ments with antidepressants do not consistently attenuate
inflammatory signs in depressed patients [182,183].
Accordingly, a recent meta-analysis showed that antide-
pressant subclasses other than SSRIs did not attenuate the
concentrations of pro-inflammatory cytokines [184]. Thus,
despite the well-established immunoregulatory effects of
antidepressants targeting inflammation (attenuate), Th1
(downregulate) and T regulatory (upregulate) functions,
clinical remission in depression is not associated with nor-
malization of immuno-inflammatory pathways [182-184].
Thus, clinical depression appears to be accompanied by a
‘resistance’ to the immunosuppressive effects of antide-
pressants [183]. This may suggest that the immuno-inflam-
matory pathways are continuously activated by processes
that cannot be blocked by antidepressants, for example, by
the autoimmune responses directed against neoantigenic
determinants [133] and increased translocation of gram
negative bacteria [157]. There is also evidence that antide-
pressants target O&NS (attenuate), antioxidants (increase)
and neuroprogressive processes (attenuate) [183]. Despite
these effects, increased activity and sensitization of
immuno-inflammatory pathways, O&NS pathways, auto-
immune responses, and neuroprogression determine in
part the staging of depression, for example, treatment
resistance and recurrence of depression [52]. Thus, these
pathways may in part explain why in many trials the clini-
cal efficacy of antidepressants does not outperform placebo
[185] and why, despite being treated with antidepressants,
depressed patients show high relapse rates [186]. There-
fore, new combinatorial treatment strategies are being
developed in clinical depression with drugs that target
inflammation, Th1 activation, O&NS and lowered antioxi-
dant levels, and/or neuroprogression, for example, statins,
acetylsalicylic acid, minocycline, zinc, N-acelyl cysteine,
curcumin, ω3 polyunsaturated fatty acids, and so on [183].
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Conclusions
Figure 3 compares sickness behavior with clinical
depression. Sickness behavior helps to eradicate the trig-
ger, has anti-inflammatory effects and is energy saving.
As such sickness behavior enhances recovery and should
be considered as part of a CIRS, which limits an over-
zealous immuno-inflammatory response to acute trig-
gers. Cross-sectionally, there are phenomenological
similarities between sickness behavior and the basic
symptoms and melancholic, physio-somatic and anxiety
symptom dimensions of clinical depression. Major dif-
ferences, however, are that malaise, a core symptom of
sickness behavior, occurs in some depressed patients
only, whereas significant pyrexia is confined to sickness
behavior. Moreover, depression is often accompanied
not by anorexia and weight loss but by hyperphagia and
weight gain. In most individuals, depression is a lifelong
disease with a tendency towards recurrent episodes
(waxing and waning), a chronic course, seasonal varia-
tion, and occasionally (hypo)manic symptoms. More-
over, sensitization and a potentially progressive
deteriorating pattern characterize the course of depres-
sion. This contrasts with sickness behavior, which is
defined as an acute, short lasting (19 to 43 days) beha-
vioral pattern.
Translational studies show that inflammatory path-
ways may account for sickness behavior as well as clini-
cal depression and, therefore, may explain the partial
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Figure 3 This figure compares sickness behavior with clinical depression. Sickness behavior is energy saving, helps to eradicate the trigger,
and has anti-inflammatory effects and as such enhances recovery and is part of a compensatory (anti)-inflammatory reflex system (CIRS).
Increases in pro-inflammatory cytokines (PICs) underpin both sickness behavior and clinical depression and thus may explain the partial
phenomenological overlap. Depression, however, is a chronic disorder with a specific course and pathophysiology and the presence of a CIRS
that downregulates the primary inflammatory response. Disorders in tryptophan catabolites (TRYCATs), cell-mediated immune (CMI) activation,
and oxidative and nitrosative stress (O&NS), and, in particular, their sequelae (O&NS damage, sensitization, autoimmunity and neuroprogression)
are the specific organic substrates of depression. While sickness behavior is a behavioral response to acute triggers, the onset of depression is
associated with multiple less-well defined trigger factors, for example, brain disorders, such as Alzheimer (AD), Huntington (HD), and Parkinson
(PD) disorder, stroke and multiple sclerosis (MS); systemic disorders, such as cardio-vascular disorder (CVD), chronic obstructive pulmonary
disorder (COPD), rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), inflammatory bowel disorder (IBD), diabetes, metabolic syndrome,
HIV infection, cancer, bacterial translocation; and conditions, such as postpartum period, hemodialysis, and interferon-(IFN)a based
immunotherapy.
Maes et al. BMC Medicine 2012, 10:66
http://www.biomedcentral.com/1741-7015/10/66
Page 13 of 19
phenomenological overlap between both conditions.
Clinical depression is accompanied by a CIRS that
downregulates the primary immuno-inflammatory
response and by a transition from inflammation and
ROS/RNS overproduction to sensitization in inflamma-
tory and CMI responses, progressive O&NS damage and
autoimmune responses. The latter pathways appear to
be the substrate of a neuroprogressive process, whereby
multiple depressive episodes cause neural tissue damage
and its functional and cognitive sequelae. Sickness beha-
vior is also induced by immuno-inflammatory pathways,
but in contrast to clinical depression, the sickness beha-
vioral complex has beneficial CIRS effects enhancing
recovery from the primary trigger. When there is no
resolution of the acute inflammatory phase within 19 to
43 days, chronic inflammation may ensue causing transi-
tion to chronic inflammatory pathology. Sickness beha-
vior plays a critical role in preventing this transition by
compensating for the negative energy balance and redir-
ecting energy to the activated immune cells.
Whereas acute infections typically elicit sickness beha-
vior, there is not much evidence that acute pathogens
play a major role in clinical depression. While traumatic
life events can induce an inflammatory state often lead-
ing to clinical depression, no association between psy-
chosocial stressors and sickness behavior has been
described. Comorbid depression increases morbidity and
mortality in patients with (auto)immune and (neuro)
inflammatory disorders, whereas sickness behavior,
when present, would tend to dampen the inflammatory
pathways.
All in all, while sickness behavior is a beneficial CIRS
response, clinical depression is a disabling, progressive
disorder. Inflammation thus provokes a Janus-faced
response with a good ‘acute’ protective inflammatory
side, involving CIRS responses, such as sickness beha-
vior, and a bad ‘chronic’ side, that can lead to clinical
depression, a chronic disorder with positive feedback
loops between (neuro)inflammation and (neuro)degen-
erative processes following less well-defined triggers.
This Janus face also represents the transition of an
inflammation-induced adaptive behavioral response that
is conserved through evolution to an inflammation-
related chronic progressive disorder, which is increasing
in prevalence in industrialized societies [187].
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